Article Text

Download PDFPDF

Treatment of IgM antibody associated polyneuropathies using rituximab
  1. A Pestronk1,
  2. J Florence1,
  3. T Miller2,
  4. R Choksi1,
  5. M T Al-Lozi1,
  6. T D Levine3
  1. 1Washington University School of Medicine, Department of Neurology, St Louis, USA
  2. 2University of Arizona, Department of Neurology, Tucson, USA
  3. 3Good Samaritan Rehabilitation Institute, Phoenix, USA
  1. Correspondence to:
 Dr A Pestronk, Washington University School of Medicine, Department of Neurology, Box 8111, 660 South Euclid Avenue, St. Louis, MO 63110, USA; 


Objectives: Polyneuropathies with associated serum IgM antibodies are often difficult to treat. Rituximab is a monoclonal antibody directed against the B cell surface membrane marker CD20. Rituximab eliminates B cells from the circulation, and, over time, could reduce cells producing autoantibodies. This study tested the ability of rituximab to produce changes in serum antibody titres, and improvement in strength, in patients with neuromuscular disorders and IgM autoantibodies.

Methods: Over a period of two years, the authors evaluated changes in strength, measured by quantitative dynamometry, and concentrations of several types of serum antibodies in patients with polyneuropathies and serum IgM autoantibodies. Twenty one patients treated with rituximab were compared with 13 untreated controls.

Results: Treatment with rituximab was followed by improved strength (an increase of mean (SEM) 23% (2%)of normal levels of strength), a reduction in serum IgM autoantibodies (to 43% (4%) of initial values), and a reduction in total levels of IgM (to 55% (4%) of initial values). There was no change in levels of serum IgG antibodies. There were no major side effects, even though B cells were virtually eliminated from the circulation for periods up to two years.

Conclusions: In patients with IgM autoantibody associated peripheral neuropathies, rituximab treatment is followed by reduced serum concentrations of IgM, but not IgG, antibodies, and by improvement in strength. Additional studies, with placebo controls and blinded outcome measures, are warranted to further test the efficacy of rituximab treatment of IgM associated polyneuropathies.

  • rituximab
  • IgM antibody
  • polyneuropathy
View Full Text

Statistics from


  • Competing interests: none declared.

  • Funding: this investigator initiated study was funded, in part, by a grant from Genentech. Partial support for this study was provided by the Washington University General Clinical Research Center (USPHS grant MO1 RR00036).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.